India Glycols: NCLT Approves Scheme of Arrangement for Demerger
India Glycols Limited received NCLT's order approving the Scheme of Arrangement for demerger. The Scheme separates Biopharma and Spirits/Biofuel undertakings into new entities. The Appointed Date is April 1, 2026. Effective Date and Record Date to be announced. Share swap ratios: 1:3 for Biopharma and 1:1 for Spirits/Biofuel.
The approval of the scheme of arrangement and demerger is a significant corporate action that will fundamentally restructure the company's business segments, impacting its operations, financials, and shareholder value.
The NCLT's approval of the Scheme of Arrangement for demerger is a positive development for the company, enabling structural changes and potential future growth for the demerged entities.
India Glycols Limited (IGL) has received the certified true copy of the order from the Hon'ble National Company Law Tribunal (NCLT), Allahabad Bench, dated July 17, 2026. This order approves the Scheme of Arrangement amongst India Glycols Limited (Demerged Company), Ennature Bio Pharma Limited (Resulting Company 1), and IGL Spirits Limited (Resulting Company 2) and their respective shareholders and creditors.
The Scheme, approved under Sections 230 to 232 of the Companies Act, 2013, was initially communicated on July 20, 2026. The NCLT's order was officially received by the company on August 20, 2026.
The Appointed Date for the approved Scheme is April 1, 2026. The Effective Date and Record Date will be determined by the Board of Directors of all involved companies and communicated in due course.
The approved Scheme involves the demerger of the Biopharma Undertaking and the Spirits and Biofuel Undertaking from India Glycols Limited into Ennature Bio Pharma Limited and IGL Spirits Limited, respectively. Upon the Scheme becoming effective, all rights, benefits, interests, and obligations related to these undertakings will be transferred to the respective resulting companies. Employees engaged in these undertakings will also be transferred, ensuring continuity of service and no less favorable terms. For the Biopharma demerger, one equity share of Rs. 5 of Resulting Company 1 will be issued for every three equity shares of Rs. 5 held in India Glycols Limited. For the Spirits and Biofuel demerger, one equity share of Rs. 5 of Resulting Company 2 will be issued for every one equity share of Rs. 5 held in India Glycols Limited. The existing equity shares held by India Glycols Limited in the resulting companies will be cancelled. The remaining business of India Glycols Limited will continue to be managed by the demerged company. The Scheme also addresses the transfer of contracts, licenses, approvals, and tax liabilities to the respective resulting companies.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.